

Published in final edited form as:

J Am Chem Soc. 2013 July 3; 135(26): 9907–9914. doi:10.1021/ja404215g.

Dephosphorylation of D-Peptide Derivatives to Form Biofunctional, Supramolecular Nanofibers/Hydrogels and Their Potential Applications for Intracellular Imaging and Intratumoral Chemotherapy

Jiayang Li[†], Yuan Gao[†], Yi Kuang[†], Junfeng Shi[†], Xuewen Du[†], Jie Zhou[†], Huaimin Wang[‡], Zhimou Yang[‡], and Bing Xu^{*,†}

[†]Department of Chemistry, Brandeis University, 415 South Street, Waltham, MA 02454, USA

[‡]State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin 300071, P. R. China

Abstract

D-peptides, as the enantiomers of the naturally occurring L-peptides, usually resist endogenous proteases and presumably insensitive to most enzymes. But it is unclear whether or how a phosphatase catalyzes the dephosphorylation from D-peptides. In this work, we examine the formation of the nanofibers of D-peptides via enzymatic dephosphorylation. By comparing the enzymatic hydrogelation of L-peptide and D-peptide based hydrogelators, we find that the chirality of the precursors of the hydrogelators affects little on the enzymatic hydrogelation resulted from the removal of phosphate group from a tyrosine phosphate residue. The attachment of a therapeutic agent (e.g., taxol) or a fluorophore (e.g., 4-nitro-2,1,3-benzoxadiazole (NBD)) to the D-peptide based hydrogelators afford a new type of biostable or biocompatible hydrogelators, which may find applications in intratumoral chemotherapy or intracellular imaging, respectively. This work, as the first comprehensive and systematic study of the unexpected enzymatic dephosphorylation of D-peptides, illustrates a useful approach to generate supramolecular hydrogels that have both biostability and other desired functions.

INTRODUCTION

This study investigates the use of alkaline phosphatase to generate supramolecular hydrogels of D-peptide derivatives and explores the potential applications of this apparently anti-intuitive enzyme-instructed self-assembly process. As the result of the self-assembly of certain small-molecules (i.e., hydrogelators^{1,2,3,4}) in water, supramolecular nanofibers act as entangled matrices for holding large amounts of water and result in hydrogels that are referred as supramolecular hydrogels.² Largely because of their inherent biocompatibility and biodegradability originated from the supramolecular (i.e., noncovalent) nature of the nanofibers formed by molecular self-assembly, supramolecular hydrogels are emerging as a relatively new class of biomaterials and are finding increased applications in biomedicine, ranging from tissue engineering,⁵ drug delivery,^{3,6} biosensing,^{7,8} wound healing,⁹ enzyme assays,¹⁰ gel electrophoresis,¹¹ nucleic acid sequestration,¹² and protein separation.¹³ Among a variety of molecules that serve as hydrogelators, small peptide-based hydrogelators¹⁴ have attracted considerable attentions because of the well-established

Corresponding Author: bxu@brandeis.edu.

Supporting Information. The details of the synthesis, NMR Spectra and LC-MS data for all compounds, rheological data, cytotoxicity data, and *in vivo* tests. This material is available free of charge via the Internet at <http://pubs.acs.org>.

synthesis procedure (e.g., SPPS)¹⁵ and the obvious biological relevance of peptides. Most of the peptide-based hydrogelators, being made of L-amino acids (i.e., L-peptides), not only preserve the biological functions of a peptide motif, but also serve as the native substrates of enzymes.

As an alternative process of the use of enzymes to cross-link polymers to cause rapid hydrogelation,¹⁶ small peptides made of L-amino acid residues undergo a process referred to as enzymatic hydrogelation that the solution of a precursor of hydrogelator, upon the addition of an enzyme, turns into the gel of the corresponding hydrogelator.¹⁷ As a useful strategy for generating supramolecular nanofibers/hydrogels, enzymatic hydrogelation has already found a wide range of applications, such as screening the inhibitors of enzymes,¹⁸ measuring enzyme activity,⁸ modulating biomineralization,¹⁹ typing bacteria,²⁰ delivering drugs or proteins,^{21,22} stabilizing enzymes,²³ and regulating the fate of cells.²⁴ Despite the merits of L-peptides as the substrates for enzymatic hydrogelation, L-peptides, however, are susceptible to degradation catalyzed by a variety of endogenous proteases, which limits the applications of supramolecular hydrogels when long-term biostability is required (such as controlled drug release,^{6,25} intracellular imaging,²⁶ or other *in vivo* applications). Therefore, it is advantageous to develop a system that not only undergoes enzymatic hydrogelation, but also forms hydrogels or nanofibers that are stable for a prolonged period inside cells or *in vivo*. Among the strategies for improving the stability of peptidic materials, the use of D-amino acid to replace L-amino acid is an effective one.²⁷ In addition to protease resistance, D-peptides also have considerable biological relevance.²⁸ For example, D-peptides can play a special role in defense mechanisms as “alien” agents from other organisms,²⁹ act as potent inhibitors to inhibit HIV-1 entry,³⁰ inhibit tumor cell migration,³¹ reduce adverse drug reactions (ADRs),⁴ control the formation and disassembly of bacterial biofilms,³² bind to DNA,³³ form β -sheet,³⁴ and dissociate Alzheimer’s amyloid to reduce the cytotoxicity induced by amyloid.³⁵

The merits of D-peptides encourage us to explore the D-amino acid-based supramolecular hydrogels, which would provide stable scaffolds for long-term drug release. Our previous works show that D-peptide-based hydrogels are resistant to protease while the corresponding L-amino acid-derived molecules undergo proteolytic hydrolysis. Recently, we also have found that D-peptides are able to improve the selectivity of non-steroid anti-inflammatory drugs (NSAID) and the D-peptide derivatives can serve as the substrate of an enzyme for hydrogelation catalyzed by alkaline phosphatase (ALP).⁴ However, it is unclear why and how the D-peptide derivatives serve as the substrates of phosphatases for hydrogelation and what other potential applications are. To address these unanswered questions, we synthesized the precursors of hydrogelators that are made of D-amino acid residues or L-amino acid residues and evaluated the formation of the nanofibers of the hydrogelators via enzymatic dephosphorylation of this pair of enantiomeric substrates. Our results from kinetic studies performed by ³¹P NMR and rheology indicate that the chirality of the precursors affects little on the enzymatic hydrogelation when the dephosphorylation occurs from the L- or D-tyrosine phosphate residue of the precursors. Moreover, the attachment of therapeutic agents or fluorophores to the side chain of the phosphorylated D-peptides results in new precursors, which confer biostable or biocompatible hydrogels/nanofibers that may find applications in intratumoral chemotherapy or intracellular imaging. This work, as the first study that confirms the enzymatic hydrogelation of D-peptides and L-peptides to occur at almost the same rate, illustrates a useful approach and provides a new class of molecular platforms for generating supramolecular hydrogels that have both biostability and other desired functions for potential application inside cells or *in vivo*.

RESULTS AND DISCUSSION

Molecular Design

In our previous studies, we have found that small dipeptide derivative, 2-(naphthalen-2-yl)acetic-Phe-Phe (NapFF) is an excellent motif for enabling self-assembly and hydrogelation due to its strong supramolecular interactions arising from aromatic-aromatic interactions and hydrogen bonds among the molecules.³⁶ Since lysine (K) possesses an ϵ -amine site for the attachment of biofunctional molecules on the side chain, and tyrosine phosphate (Y(p)) offers a handle for enzyme instructed hydrogelation, the incorporation of K and Y(p) with NapFF provides a versatile hydrogelator precursor NapFFKY(p) (**1a**), which undergoes enzymatic hydrogelation. Those studies suggest that one can use D-amino acids—D-Phe (f), D-Lys (k), and D-Tyr phosphate (y(p))—to replace the corresponding L-amino acids for making a more biostable precursor Napffky(p) (**1b**). To evaluate whether the dephosphorylation of D-tyrosine phosphate (y(p)) from the D-peptide by the phosphatase still would be possible, we first examine the binding of the tyrosine phosphate on **1a** or **1b** with ALP according to the crystal structure of ALP.³⁷ With the phosphate groups (represented by the yellow and red spheres in Figure 1) being anchored to the active site of ALP (represented by the solid ribbons in Figure 1), the structures of the phosphatase that binds with L-peptide/D-peptide based precursors **1a** and **1b** are shown in Figure 1A and Figure 1B, respectively. Although there are stereochemical differences between **1a** and **1b**, the phosphate groups appear to be able to bind the same active site without any hinderance. According to the top view (Figure 1C), the opening in the structure of ALP is large enough to accommodate either **1a** or **1b**. Similarly, the side view (Figure 1D) clearly indicates that the phosphate groups on **1a** or **1b** are able to bind the active site of ALP. Thus, we choose to investigate the enzymatic hydrogelation of **1b**, and to compare it with **1a** by the rate of formation, morphology, and viscoelastic property of the corresponding hydrogels.

To explore the biological and biomedical applications of **1b**, we attach small functional molecules, such as 4-nitro-2,1,3-benzoxadiazole (NBD), a fluorophore used in cell imaging, and taxol, a clinically-used anti-cancer drug, to **1b**. Our previous works have established the synthetic route for the incorporation of the fluorophore or taxol to the hydrogelator precursor **1a**. For example, we have developed a fluorescent hydrogelator precursor that undergoes intracellular enzymatic hydrogelation and forms fluorescent molecular aggregates inside cells.³⁸ We have also attached taxol to **1a** to afford the precursor of an anticancer hydrogelator that increases the solubility of taxol and achieves controlled drug delivery.²² These studies offer the necessary synthetic routes that allow us to conjugate precursor **1b** with NBD group or taxol, which affords Napffk(NBD)y(p) (**4b**) or Napffk(taxol)y(p) (**9b**). These molecules represent a new type of precursors to result in the hydrogelators that are both biostable and multifunctional.

Synthesis

Scheme 1 shows the chemical structures of precursors **1a** and **1b**. Utilizing Fmoc-protected D-amino acids, we prepare **1b** by standard solid phase synthesis with 2-chlorotrityl chloride resin (100~200 mesh and 0.3~0.8 mmol/g), followed by HPLC purification. We conjugate NBD group at the side chain of lysine to afford the precursor Napffk(NBD)y(p) (**4b**). As shown in Scheme 1, we dissolve 7-chloro-4-nitro-2,1,3-benzoxadiazole (NBD-Cl) (**3**) in methanol, followed by adding the basic aqueous solution of **1b** (pH 9). The reaction of the mixed solution at 50 °C for 2 hours yields **4b** as red precipitates after work-up and purification by reverse phase HPLC.

Using a similar approach, we obtain the conjugate of taxol and **1b**. As shown in Scheme 1, we add succinic an- hydride and 4-dimethylamino-pyridine (DMAP) into the clear solution

of taxol (**10**) in pyridine. After stirring the mixture at room temperature overnight, we extract the solution with dichloromethane (DCM) and obtain taxol-succinic acid (**7**). The conjugation of **7** and *N*-hydroxysuccinimide (NHS) with the aid of *N,N'*-dicyclohexylcarbodiimide (DCC) affords taxol-succinic-NHS ester (**8**). Purified with column chromatography, we collect pure **8** and re-dissolve it with acetone. Then we add the acetone solution into a basic aqueous solution (pH 8.5) of **5b**, which reacts for 24 hours. After working up the reaction and using reverse phase HPLC for the purification, we obtain compound **9b** as the conjugate of taxol and **1b**. These results indicate that it is convenient to apply the synthesis of L-peptidic precursors for producing the corresponding D-peptidic precursors.

Hydrogelation of the D-peptidic hydrogelator (**2b**)

To investigate the enzymatic hydrogelation of the D-peptidic precursor **1b**, we prepare a series of hydrogels formed by using ALP to treat **1b** at different concentrations. After dissolving 1.0, 2.0, 3.0, 4.0, and 5.0 mg of **1b** in 0.5 mL of water (pH 7.6), respectively, we obtain clear solutions of **1b** with different concentrations. The treatment of the solutions of **1b** with ALP (1.0 U/mL) affords the molecules of hydrogelator **2b**, which are less soluble than **1b** and thus self-assemble in water to form hydrogels when the concentrations of **2b** are sufficient. As shown in Figure 2, except the solution of 0.2 wt% of **1b**, solutions of **1b** with the concentration of 0.4, 0.6, 0.8, or 1.0 wt% form a stable transparent hydrogel within 24 h after the addition of 1.0 U/mL ALP into the solutions. Furthermore, as shown of the optical images in Figure 2, the higher concentration of the solutions of **1b** gives the less transparent hydrogels of **2b**, which also exhibits little birefringence (Figure S6), indicating that excess overlapping of the nanofibers to form large domains in the hydrogels of **2b** cause the scattering of the light.

Being complementary to the optical images that serve as a simple way for proving the macroscopic phase transition (i.e., hydrogelation) triggered by the addition of ALP, transmission electron microscopy (TEM) images reveal the ordered nanostructures (e.g., nanofibers), formed by the self-assembly of the hydrogelators, that lead to hydrogelation. As shown in Figure 2, the TEM images of all the hydrogels, which consist of different concentrations of **2b**, exhibit long, flexible, and uniform nanofibers that entangle to form stable networks. With the increase of the concentrations of hydrogelator **2b** (0.4, 0.6, 0.8, and 1.0 wt%), the densities of the nanofibers in the hydrogels increase, but the widths of the nanofibers in the hydrogels remain similar (around 9 ± 2 nm). These results indicate that concentration of the hydrogelator **2b** hardly affect the self-assembling process controlled by the enzymatic hydrogelation so that the nanofibers exhibit similar morphology regardless the concentrations of the precursor solutions. The concentrations of the hydrogelators correlate well with the densities of nanofibers, which should match with the viscoelastic behaviors of the hydrogels.

The oscillatory rheological measurement of the hydrogels of **2b** agrees with the density of the nanofibers in the hydrogels. The dynamic strain sweep, under constant oscillation frequencies and various oscillation strains, indicates that the storage moduli (G' 's) of all these hydrogels are independent to strain until their critical strains reach, and G' 's start to decrease drastically due to the breakdown of the networks of the hydrogels. After obtaining the maximum G' 's of the hydrogels in dynamic strain sweep, we measure the frequency dependence of their storage moduli (G' 's) and loss moduli (G'' 's) using dynamic frequency sweep at constant oscillation strain (the strain for maximum G' 's) and temperature (25 °C) but varying oscillation frequency (0.1~200 rad/s). All the hydrogels of **2b** exhibit viscoelastic properties of solid-like materials, evidenced by that the values of their G' 's are significant higher (more than five times) than those of their G'' 's and are independent of the

frequency during dynamic frequency sweep (Figure S8). As listed in Table 1, the hydrogels of **2b** at the concentrations of 0.4, 0.6, 0.8, and 1.0 wt% exhibit strains of 4.7%, 5.0%, 14%, and 16%, respectively. In addition, their values of G' (at the frequency of 6.28 rad/s) in dynamic frequency sweep are 6.5×10^2 Pa, 1.8×10^3 Pa, 2.7×10^3 Pa, and 3.8×10^3 Pa. While the critical strains of the resulting hydrogels of **2b** show little correlation with the concentrations of the hydrogelators (Figure S8C and S8D), the storage moduli of hydrogels of **2b** increase with the concentrations of **2b**. This result agrees with that more physical cross-linking of the nanofibers at high concentrations of the hydrogelators.

The comparisons of L and D enantiomers of the precursors and hydrogelators

The comparison of the enzymatic hydrogelation process of **1a** and **1b** under the same conditions reveals that the chirality of **1a** and **1b** affects little on their dephosphorylation and the subsequent hydrogelation. To evaluate the rate of enzymatic hydrogelation process, we use ^{31}P NMR and rheology to study the transformation of the precursors **1a** and **1b** upon the treatment of ALP (Figure 3). We first dissolve 10 mg of **1a** and **1b** into 1.0 mL of water at pH 7.6, respectively, to afford clear solutions with concentrations of 1.0 wt%. Once adding 0.02 U/mL of alkaline phosphates, we immediately monitor the solutions of **1a** and **1b** by ^{31}P NMR and oscillatory rheology at 25 °C. The ^{31}P NMR spectra at 3 min, 1 h, 2 h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 24h, and 48h indicate that the phosphate groups on the L-tyrosine of **1a** and D-tyrosine **1b** ($\delta = -2.7$) become free phosphates ($\delta = 0.0$) at almost same rate, and dephosphorylation finishes after 48 hours. This result suggests that the precursors **1a** and **1b** undergo dephosphorylation with similar rates upon being treated with ALP. Figures 3C and 3D display the time dependent rheology studies of **1a** and **1b**. At the beginning, values of G'' are higher than the values of G' for the solutions of **1a** and **1b**, indicating both of them are fluids. However, as **1a** and **1b** slowly turn into hydrogelators **2a** and **2b** by enzymatic dephosphorylation, the solutions start to form solid-like hydrogels with values of G' become higher than those of G'' . The gelation points for **2a** and **2b**, at where G' 's intersect with G'' 's, are both achieved around 5 hours after the addition of enzyme. This result, together with the ^{31}P NMR experiment, suggests that the chirality of **1a** and **1b** exhibits almost the same influence on the enzymatic hydrogelation catalyzed by ALP. The oscillatory shear during rheological measurement may accelerates enzymatic dephosphorylation so that the gelation points reach at the time (5 hours) much shorter than the time for completely dephosphorylation during the NMR experiment (48 hours).

After comparing the rate of the dephosphorylation of the L- and D-enantiomeric precursors (**1a** and **1b**), we examine the morphology of the microstructures and viscoelastic properties of the corresponding hydrogels (**2a** and **2b**). By sonication, we dissolve 2.0 mg of **1a** or **1b** into 0.5 mL of water at pH 7.6 to afford a clear solution. The addition of 1.0 U/mL of ALP into the solution of **1a** or **1b** turns the hydrogelator precursor to its corresponding hydrogelator, **2a** or **2b**, which results in a transparent hydrogel (0.4 wt%) within 24 hours. As shown in Figure 4A and 4B, both hydrogelators **2a** and **2b** self-assemble to form long, flexible, and uniform nanofibers with average width around 8 ± 2 nm, which entangle to develop physically cross-linked networks and to afford stable hydrogels. The similarity of the nanofibers in these two hydrogels indicates that chirality of **2a** and **2b** has little influence on the morphology of their nanofibers. Oscillatory rheology of the hydrogels of **2a** and **2b** indicates that both hydrogels behave as solid-like materials that have storage moduli (G') to be significantly higher than loss moduli (G'') and exhibit weak frequency dependence in dynamic frequency sweep (Figure 4C and 4D). As shown in Table 1, hydrogels of **2a** and **2b** have critical strains of 3.7% and 4.7% during the dynamic strain sweep, and their values of G' (at the frequency of 6.28 rad/s) in dynamic frequency sweep are 8.6×10^2 Pa and 6.5×10^2 Pa, respectively. These results suggest that the chirality of these two hydrogelators causes negligible differences on the viscoelastic properties of the corresponding hydrogels.

The application of the D-enantiomer hydrogelator (**1b**) for potential intracellular imaging

According to the molecular design, the attachment of functional molecules to **1b** broadens the scope of the applications of supramolecular hydrogelators in cells or *in vivo*. We first examine the feasibility and characteristic of the use **4b** for imaging intracellular self-assembly of D-peptidic hydrogelators. After dissolving 2.0 mg of **4b** into 0.5 mL of water at pH 7.4, we treat the clear orange solution with 20.0 U/mL of ALP, which turns **4b** into the fluorescent hydrogelator **5b**. The self-assembly of **5b** affords a transparent orange hydrogel (Figure 5A, inset) that is stable over weeks. The TEM image of hydrogel of **5b** exhibits long and uniform nanofibers with average width of 8 ± 2 nm that entangle to afford stable network (Figure 5A). According to our previous study, the unassociated molecules of NBD containing hydrogelators in aqueous solutions exhibit little fluorescence unless they aggregate to form nanofibers.³⁸ This important feature makes NBD containing hydrogelator be a useful candidate for imaging molecular self-assembly inside cells.

After treating HeLa cells with 500 μ M of hydrogelator precursor **4b** for two minutes, we observe strong fluorescence emerging from the region near the nuclei of cells (Figure 5B, C), suggesting that the self-assembly of **5b** results in formation of the nanofibers of **5b** around the endoplasmic reticulum (ER). There is little fluorescence outside the cells, suggesting the lack of dephosphorylation and/or self-assembly of **5b**. To confirm that the dephosphorylation of **4b** and self-assembly of **5b** take place in ER, we use 25 μ M of CinnGEL 2Me to inhibit protein tyrosine phosphatase-1B (PTP1B),³⁹ a highly efficient phosphatase located at the outer membrane of ER, when the HeLa cells are incubated with **4b** (500 μ M). As shown in Figure 5D, the addition of the inhibitor of PTP1B significantly decreases and delays the fluorescence inside cells, confirming that the dephosphorylation of **4b** and the self-assembly of **5b** occur at ER. As shown by the time sequence fluorescent images of the HeLa cells incubated with **4b** in the absence of the PTP1B inhibitor (Figure S11), most of the cells exhibit strong fluorescence after treated with **4b** for only 2 minutes. Even being incubated with the presence of PTP1B inhibitor, the cells still show partial fluorescence after 5 minutes of the incubation. Apparently, the fluorescence of the nanofibers in the HeLa cells treated by the D-peptide precursor (**4b**) emerges much faster than that of L-peptide precursor (**4a**) (which takes about 15 min³⁸ in the presence of CinnGEL 2Me). This result agrees with that the resulted D-peptide hydrogelator (**5b**) is more resistant to proteolytic degradation than the L-peptide hydrogelator (**5a**) does.

The application of D-enantiomer hydrogelator (**1b**) for potential intratumoral chemotherapy

Typically, after dissolving 9.0 mg of **9b** in 0.5 mL of water at pH 7.4 by sonication, we add ALP (1.0 U/mL) into the solution of **9b** to obtain hydrogelator **10b**, which forms a stable and semitransparent hydrogel (Figure 6A). This result differs slightly from the behavior of precursor **9a** that undergoes enzymatic hydrogelation at the concentration of 1.0 wt%,²² suggesting that precursor **9b** (having a concentration up to 1.8 wt% for enzymatic hydrogelation) and hydrogelator **10b** exhibit relatively good solubility. This subtle increase of the solubility should increase the amount of taxol in the hydrogel. The TEM image of the hydrogel **10b** shows the uniform nanofibers with the average width of 9 ± 2 nm. To determine the efficacies of taxol after conjugating it into the hydrogelator, we use MTT assays to examine the viability of HeLa cells incubated with taxol (**6**), **9b**, and **10b** for 72 hours at 37°C. Figure 6B shows the IC₅₀ values of **6**, **9b**, and **10b**, which are 45.8 nM, 61.9 nM, and 105.9 nM, respectively. This result suggests that the conjugation of taxol to the D-peptide essentially preserve the anti-tumor activity of taxol, thus encouraging us to carry out *in vivo* test of **10b** on a mouse model.⁴⁰

As expected, both L- and D-peptide based hydrogels of **10a** and **10b** exhibit similar anti-tumor activities up to 12 days of intratumoral injection of the hydrogels. After inoculating

female Balb/c mice with 2×10^5 of 4T1-luciferase cells in the mammary fat pad, we allow tumors grow until their sizes reach about 500 mm³, and randomly divide them into different treatment groups: (1) intravenous injections of PBS vehicle control; (2) intravenous injection of 4×10 mg/kg Taxol[®] every other day from day 0 for indicated times; (3) a single intratumoral injection of 10 mg/kg taxol containing hydrogels in 40 μ L volume. With the treatments of **6** (taxol), **10a**, **10b**, or PBS buffer (control) for 14 days, we monitor the relative tumor sizes (calculated by the formula: tumor volume = length \times width \times (Length + Width) / 2) and relative weights of mice every two days. Due to the toxicity of clinical taxol (formulated with Cremophor EL),⁴¹ the single injection of 40 mg/kg of Taxol[®] may cause the death of mouse immediately. Therefore, we have to divide 40 mg/kg of **6** into four injections with each injection of 10 mg/kg. As shown in Figure 6C, the intravenous injections of 40 mg/kg of **6** every other day from day 0 results in the relative tumor sizes to be smaller than those of the control group after day 8. In contrast, the intratumoral injections of the hydrogel **10a** or **10b** at only one dose of 10 mg/kg in the mice at day 0, which may sustain for one month, reduce the relative tumor sizes on the mice more significantly than those of the controls after day 2. At day 14, although the relative tumor sizes in the groups injected with **6** and the hydrogel of **10a** are similar with the PBS buffer control group, the relative tumor size in the group injected with the hydrogel of **10b** is statistically smaller than the control. This result suggests that the hydrogel of **10b** exhibits higher anti-tumor efficacy than **10a** or **6** does. Figure 6D shows the relative weights of mice during these 14 days treatment, suggesting that the intratumoral injection of hydrogels of **10a** and **10b**, only once, certainly limit the side effect of taxol to the mice. These results support that the local injection of the hydrogels appears to achieve long term drug release with higher efficacy and better biocompatibility than the intravenous injection of taxol.⁴⁰ This promising result warrants further investigation of the D-peptidic hydrogels of taxol on animal models.

CONCLUSION

In conclusion, taking the advantages of D-amino acids, we have developed biostable and biocompatible supramolecular hydrogels made of D-amino acid residues. Similar to other D-amino acid containing peptides, **1b** resists to protease while the corresponding L-amino acid derived molecule (**1a**) undergo proteolytic hydrolysis (Figure S12). Although these D-peptidic derivatives are intrinsically resistant to proteolytic hydrolysis, which make the hydrogels as stable platform materials for long term biomedical applications, D-peptide based hydrogelator precursor still acts as a substrate of phosphatase for enzyme-instructed self-assembly. While it appears unexpected that the rates of dephosphorylation of L-peptide and D-peptide precursors are comparable, the crystal structure of the phosphatase confirms it is feasible for such an observation. This work, thus, illustrates a protein structure-based approach for designing the substrates of enzyme-instructed self-assembly and hydrogelation. While the conjugation of **1b** with taxol affords a biostable hydrogel that exhibits improved drug efficacy in anti-cancer activity, the fast accumulation of molecular nanofibers of D-peptide (in the case of **4b**) is particularly intriguing because it indicates the introduction of D-peptide may result in certain biological effects much faster than intuitively thought, which is a subject worthwhile for the further exploration.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was partially supported by HFSP (RGP0056 /2008), a start-up fund from Brandeis University, and NIH (R01CA142746) The TEM images were taken at the Brandeis EM and Optical Imaging facilities.

References

- (a) Terech P, Weiss RG. *Chem Rev.* 1997; 97:3133–3159. [PubMed: 11851487] (b) Heeres A, van der Pol C, Stuart MCA, Friggeri A, Feringa BL, van Esch J. *J Am Chem Soc.* 2003; 125:14252–14253. [PubMed: 14624554] (c) Mukhopadhyay S, Maitra U, Ira, Krishnamoorthy G, Schmidt J, Talmon Y. *J Am Chem Soc.* 2004; 126:15905–15914. [PubMed: 15571416] (d) Zhang Y, Yang ZM, Yuan F, Gu HW, Gao P, Xu B. *J Am Chem Soc.* 2004; 126:15028–15029. [PubMed: 15547990] (e) Vemula PK, Li J, John G. *J Am Chem Soc.* 2006; 128:8932–8938. [PubMed: 16819889] (f) Yang ZM, Liang GL, Wang L, Xu B. *J Am Chem Soc.* 2006; 128:3038–3043. [PubMed: 16506785] (g) Cai W, Wang GT, Du P, Wang RX, Jiang XK, Li ZT. *J Am Chem Soc.* 2008; 130:13450–13459. [PubMed: 18788803] (h) Ma ML, Kuang Y, Gao Y, Zhang Y, Gao P, Xu B. *J Am Chem Soc.* 2010; 132:2719–2728. [PubMed: 20131781] (i) Li XM, Kuang Y, Shi JF, Gao Y, Lin HC, Xu B. *J Am Chem Soc.* 2011; 133:17513–17518. [PubMed: 21928792] (j) Zheng WT, Gao J, Song LJ, Chen CY, Guan D, Wang ZH, Li ZB, Kong DL, Yang ZM. *J Am Chem Soc.* 2013; 135:266–271. [PubMed: 23240879] (k) Xing BG, Yu CW, Chow KH, Ho PL, Fu DG, Xu B. *J Am Chem Soc.* 2002; 124:14846–14847. [PubMed: 12475316]
- Estroff LA, Hamilton AD. *Chem Rev.* 2004; 104:1201–1217. [PubMed: 15008620]
- (a) Komatsu H, Matsumoto S, Tamaru S, Kaneko K, Ikeda M, Hamachi I. *J Am Chem Soc.* 2009; 131:5580–5585. [PubMed: 19331364] (b) Boekhoven J, Koot M, Wezendonk TA, Eelkema R, van Esch JH. *J Am Chem Soc.* 2012; 134:12908–12911.
- Li JY, Kuang Y, Gao Y, Du XW, Shi JF, Xu B. *J Am Chem Soc.* 2013; 135:542–545. [PubMed: 23136972]
- (a) Hartgerink JD, Beniash E, Stupp SI. *Science.* 2001; 294:1684–1688. [PubMed: 11721046] (b) Holmes TC, de Lacalle S, Su X, Liu GS, Rich A, Zhang SG. *Proc Natl Acad Sci U S A.* 2000; 97:6728–6733. [PubMed: 10841570] (c) Haines LA, Rajagopal K, Ozbas B, Salick DA, Pochan DJ, Schneider JP. *J Am Chem Soc.* 2005; 127:17025–17029. [PubMed: 16316249] (d) Galler KM, Aulisa L, Regan KR, D'Souza RN, Hartgerink JD. *J Am Chem Soc.* 2010; 132:3217–3223. [PubMed: 20158218]
- Zhao F, Ma ML, Xu B. *Chem Soc Rev.* 2009; 38:883–891. [PubMed: 19421568]
- (a) Wada A, Tamaru S, Ikeda M, Hamachi I. *J Am Chem Soc.* 2009; 131:5321–5330. [PubMed: 19351208] (b) Rajagopalan A, Kroutil W. *Mater Today.* 2011; 14:144–152.
- Bremmer SC, Chen J, McNeil AJ, Soellner MB. *Chem Commun.* 2012; 48:5482–5484.
- Yang ZM, Liang GL, Ma ML, Abbah AS, Lu WW, Xu B. *Chem Commun.* 2007:843–845.
- Kiyonaka S, Sada K, Yoshimura I, Shinkai S, Kato N, Hamachi I. *Nat Mater.* 2004; 3:58–64. [PubMed: 14661016]
- Yamamichi S, Jinno Y, Haraya N, Oyoshi T, Tomitori H, Kashiwagi K, Yamanaka M. *Chem Commun.* 2011; 47:10344–10346.
- Yang ZM, Kuang Y, Li XM, Zhou N, Zhang Y, Xu B. *Chem Commun.* 2012; 48:9257–9259.
- Gao Y, Long MJC, Shi JF, Hedstrom L, Xu B. *Chem Commun.* 2012; 48:8404–8406.
- (a) Cui HG, Webber MJ, Stupp SI. *Biopolymers.* 2010; 94:1–18. [PubMed: 20091874] (b) Williams RJ, Mart RJ, Ulijn RV. *Biopolymers.* 2010; 94:107–117. [PubMed: 20091879] (c) Rajagopal K, Ozbas B, Pochan DJ, Schneider JP. *Biopolymers.* 2005; 80:487–487. (d) Gao Y, Yang ZM, Kuang Y, Ma ML, Li JY, Zhao F, Xu B. *Biopolymers.* 2010; 94:19–31. [PubMed: 20091873]
- Chan, WC.; White, P. *Fmoc Solid Phase Peptide Synthesis: A Practical Approach.* OUP Oxford; 2000.
- Hu BH, Messersmith PB. *J Am Chem Soc.* 2003; 125:14298–14299. [PubMed: 14624577]
- (a) Yang ZM, Gu HW, Fu DG, Gao P, Lam JK, Xu B. *Adv Mater.* 2004; 16:1440. (b) Toledano S, Williams RJ, Jayawarna V, Ulijn RV. *J Am Chem Soc.* 2006; 128:1070–1071. [PubMed: 16433511] (c) Yang Z, Liang G, Xu B. *Acc Chem Res.* 2008; 41:315–326. [PubMed: 18205323] (d) Hirst AR, Roy S, Arora M, Das AK, Hodson N, Murray P, Marshall S, Javid N, Sefcik J, Boekhoven J, van Esch JH, Santabarbara S, Hunt NT, Ulijn RV. *Nat Chem.* 2010; 2:1089–1094. [PubMed: 21107375] (e) Williams RJ, Smith AM, Collins R, Hodson N, Das AK, Ulijn RV. *Nat Nanotechnol.* 2009; 4:19–24. [PubMed: 19119277]

18. Yang ZM, Xu B. *Chem Commun.* 2004:2424–2425.
19. Schnepf ZAC, Gonzalez-McQuire R, Mann S. *Adv Mater.* 2006; 18:1869.
20. Yang ZM, Ho PL, Liang GL, Chow KH, Wang QG, Cao Y, Guo ZH, Xu B. *J Am Chem Soc.* 2007; 129:266–267. [PubMed: 17212393]
21. (a) Vemula PK, Cruikshank GA, Karp JM, John G. *Biomaterials.* 2009; 30:383–393. [PubMed: 18930313] (b) Williams RJ, Hall TE, Glattauer V, White J, Pasic PJ, Sorensen AB, Waddington L, McLean KM, Currie PD, Hartley PG. *Biomaterials.* 2011; 32:5304–5310. [PubMed: 21531457]
22. Gao Y, Kuang Y, Guo ZF, Guo ZH, Krauss IJ, Xu B. *J Am Chem Soc.* 2009; 131:13576. [PubMed: 19731909]
23. Wang QG, Yang ZM, Gao Y, Ge WW, Wang L, Xu B. *Soft Matter.* 2008; 4:550–553.
24. (a) Yang ZM, Xu KM, Guo ZF, Guo ZH, Xu B. *Adv Mater.* 2007; 19:3152. (b) Yang Z, Liang G, Guo Z, Xu B. *Angew Chem Intl Ed.* 2007; 46:8216–8219.
25. Cheetham AG, Zhang PC, Lin YA, Lock LL, Cui HG. *J Am Chem Soc.* 2013; 135:2907–2910. [PubMed: 23379791]
26. Gao Y, Shi JF, Yuan D, Xu B. *Nat Commun.* 2012; 3
27. (a) Li XM, Du XW, Li JY, Gao Y, Pan Y, Shi JF, Zhou N, Xu B. *Langmuir.* 2012; 28:13512–13517. [PubMed: 22906360] (b) Liang GL, Yang ZM, Zhang RJ, Li LH, Fan YJ, Kuang Y, Gao Y, Wang T, Lu WW, Xu B. *Langmuir.* 2009; 25:8419–8422. [PubMed: 20050040]
28. (a) Van Regenmortel MHV, Muller S. *Curr Opin Biotechnol.* 1998; 9:377–382. [PubMed: 9720264] (b) Nair DT, Kaur KJ, Singh K, Mukherjee P, Rajagopal D, George A, Bal V, Rath S, Rao KVS, Salunke DM. *J Immunol.* 2003; 170:1362–1373. [PubMed: 12538696]
29. Konno, R. *D-amino acids: a new frontier in amino acids and protein research : practical methods and protocols.* Vol. 35. Nova Science Publishers; 2007.
30. Welch BD, VanDemark AP, Heroux A, Hill CP, Kay MS. *Proc Natl Acad Sci U S A.* 2007; 104:16828–16833. [PubMed: 17942675]
31. (a) Sroka TC, Pennington ME, Cress AE. *Carcinogenesis.* 2006; 27:1748–1757. [PubMed: 16537560] (b) Liu M, Li C, Pazgier M, Li CQ, Mao YB, Lv YF, Gu B, Wei G, Yuan WR, Zhan CY, Lu WY. *Proc Natl Acad Sci U S A.* 2010; 107:14321–14326. [PubMed: 20660730]
32. Kolodkin-Gal I, Romero D, Cao SG, Clardy J, Kolter R, Losick R. *Science.* 2010; 328:627–629. [PubMed: 20431016]
33. (a) Reich Z, Schramm O, Brumfeld V, Minsky A. *J Am Chem Soc.* 1996; 118:6345–6349. (b) Morii T, Tanaka T, Sato S, Hagihara M, Aizawa Y, Makino K. *J Am Chem Soc.* 2002; 124:180–181. [PubMed: 11782163] (c) Michaud M, Jourdan E, Villet A, Ravel A, Grosset C, Peyrin E. *J Am Chem Soc.* 2003; 125:8672–8679. [PubMed: 12848575]
34. Swanekamp RJ, DiMaio JTM, Bowerman CJ, Nilsson BL. *J Am Chem Soc.* 2012; 134:5556–5559. [PubMed: 22420540]
35. (a) Esteras-Chopo A, Pastor MT, Serrano L, de la Paz ML. *J Mol Biol.* 2008; 377:1372–1381. [PubMed: 18328503] (b) Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boule M, Sarazin P, Stea D, Lacombe D, Tremblay P, Gervais F. *J Biol Chem.* 2003; 278:34874–34881. [PubMed: 12840031]
36. (a) Lehn JM. *Angew Chem Int Ed Engl.* 1988; 27:89–112. (b) Whitesides GM, Grzybowski B. *Science.* 2002; 295:2418–2421. [PubMed: 11923529]
37. Coleman JE. *Annu Rev Biophys Biomol Struct.* 1992; 21:441–483. [PubMed: 1525473]
38. Gao Y, Shi JF, Yuan D, Xu B. *Nat Commun.* 2012; 3:1033. [PubMed: 22929790]
39. Frangioni JV, Beahm PH, Shifrin V, Jost CA, Neel BG. *Cell.* 1992; 68:545–560. [PubMed: 1739967]
40. Wang HM, Wei J, Yang CB, Zhao HY, Li DX, Yin ZN, Yang ZM. *Biomaterials.* 2012; 33:5848–5853. [PubMed: 22607913]
41. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. *Semin Oncol.* 1993; 20:1–15. [PubMed: 8102012]




Figure 1. The binding of the phosphate precursors (presented as CPK model: yellow, phosphorous; red, oxygen.) to the active site of an ALP (presented as solid ribbons). (A) L-peptide based precursor (**1a**) and (B) D-peptide based precursor (**1b**) binding to the phosphatase. (C) Top view and (D) side view of **1a** (green) and **1b** (dark pink) in the active site. Purple atoms represent the parts of **1a** and **1b** that would occupy same space in the active site.




Figure 2. The TEM images of the hydrogels formed by using ALP (1.0 U/mL) to treat **1b** at pH 7.6 and concentrations of (A) 0.4 wt%, (B) 0.6 wt% (C) 0.8% wt, and (D) 1.0 wt%. Inset: optical images. Scale bar is 100 nm.




Figure 3. The ^{31}P NMR shows the conversion of 1.0 wt% of (A) **1a** and (B) **1b** catalyzed by the phosphatase (0.02 U/mL) at pH 7.6 at 3 minutes and 4, 12, 24, and 48 h; The time dependent rheology study of 1.0 wt% of (C) **1a** and (D) **1b** catalyzed by the phosphatase (0.02 U/mL) at pH 7.6.




Figure 4. The optical images and TEM images of the hydrogels formed by using ALP (1.0 U/mL) to treat 0.4 wt% of (A) **1a** and (B) **1b** at pH 7.6. (C) The strain sweep and (D) the frequency sweep of the hydrogels **2a** and **2b**.




Figure 5. (A) The optical image and TEM image of hydrogel formed by 0.4 wt% of **4b** at pH 7.4 upon the catalysis of ALP (20.0 U/ml). (B) The fluorescent confocal microscope image of a HeLa cell incubated with 500 μM of **4b** in PBS buffer (scale bar is 10 μm). The fluorescent confocal microscope images of HeLa cells incubated with 500 μM of **4b** without (C) or with (D) the PTP1B inhibitor (25 μM) (scale bar is 50 μm).





Figure 6. (A) The optical and TEM images of hydrogel formed by 1.8 wt% of **10b** at pH 7.4 with the catalysis of ALP (1 U/mL) with scale of 100 nm; (B) The IC₅₀ values of **6**, **9b**, and **10b** incubated with HeLa cells after 72 h; (C) The relative tumor sizes and (D) relative weights of mice treated with **6**, **10a**, and **10b** for *in vivo* tests.



Scheme 1.

The synthetic route of the precursor of the NBD or taxol-containing hydrogelator based on a D-peptide.

Table 1

The rheological properties and TEM characteristics of the hydrogels of 2a, 2b, 5b, and 10b.

Compound	Conc. (wt%)	Dynamic Strain Sweep			Dynamic Frequency Sweep	
		Maximum G' (Pa)	Critical strain (%)	G''/G' (Pa)	G''/G' (Pa)	Width of fiber (nm)
2a	0.4	7.2×10^2	3.7		8.6×10^2	8 ± 2
2b	0.4	6.4×10^2	4.7		6.5×10^2	8 ± 2
	0.6	1.7×10^3	5.0		1.8×10^3	9 ± 2
	0.8	2.7×10^3	14		2.7×10^3	9 ± 2
	1.0	3.9×10^3	16		3.8×10^3	9 ± 2
5b^b	0.4	46	6.9		62	8 ± 2
10b^b	1.8	43	0.59		16	9 ± 2

^aThe value is taken at frequency equals 6.28 rad/s.

^bThe hydrogel is formed at pH7.4, while others are formed at pH 7.6.